Derakhshan S, Aminishakib P, Karimi A, Saffar H, Abdollahi A, Mohammadpour H, et al. High frequency of BRAF V600E mutation in Iranian population ameloblastomas. Med Oral Patol Oral Cir Bucal. 2020 Jul 1;25 (4):e502-7.
doi:10.4317/medoral.23519
https://dx.doi.org/doi:10.4317/medoral.23519
1. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007;30:645-8. |
PMid:18091060 |
2. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232:492-8. |
PMid:24374844 PMCid:PMC4255689 |
3. Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M, et al. The Mutational Profile of Unicystic Ameloblastoma. J Dent Res. 2019;98:54-60. |
PMid:30216733 |
4. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin. Cancer Res. 2014;20:5517-26. |
PMid:24993163 |
5. Fregnani ER, Perez DE, Paes de Almeida O, Fonseca FP, Soares FA, Castro-Junior G, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology. 2017;70:473-84. |
PMid:27681305 |
6. Wright JM, Vered M. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. Head Neck Pathol. 2017;11:68-77. |
PMid:28247226 PMCid:PMC5340735 |
7. Ballester LY, Cantu MD, Lim KPH, Sarabia SF, Ferguson LS, Renee Webb C, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018;36:307-15. |
PMid:28219109 PMCid:PMC6886693 |
8. Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH 3rd, Longshore JW. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Human Pathol. 2014;45:2281-93. |
PMid:25228337 |
9. Abe M, Zong L, Abe T, Takeshima H, Ji J, Ushijima T, et al. BRAF inhibitor: a novel therapy for ameloblastoma in mandible. Chin J Cancer Res. 2018;30:677-8. |
PMid:30700936 PMCid:PMC6328504 |
10. Abe M, Zong L, Abe T, Hoshi K. A turning point in therapy for ameloblastomas. Oral Oncol. 2018;80:95-6. |
PMid:29548681 |
11. Diniz MG, Gomes CC, Guimarães BVA, Castro WH, Lacerda JCT, Cardoso SV. Assessment of BRAF-V600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biol. 2015;36:5649-53. |
PMid:25854168 |
12. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46:722-5. |
PMid:24859340 PMCid:PMC4418232 |
13. Gültekin SE, Aziz R, Heydt C, Sengüven B, Zöller J, Safiet AF, et al. The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch. 2018;472:807-14. |
PMid:29388014 PMCid:PMC5978850 |
14. Soltani M, Tabatabaiefar MA, Mohsenifar Z, Pourreza MR, Moridnia A, Shariati L, et al. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. J Oral Pathol Med. 2018;47:86-90. |
PMid:28650588 |
15. Heikinheimo K, Kurppa KJ, Elenius K. Novel targets for the treatment of Ameloblastoma. J Dent Res. 2015;94:237-40. |
PMid:25425580 PMCid:PMC4438731 |
16. Brown NA, Betz BL. Ameloblastoma: a review of recent molecular Pathogenetic discoveries. Biomarkers in Cancer. 2015;7:19-24. |
PMid:26483612 PMCid:PMC4597444 |
17. Shirsat PM, Bansal S, Prasad P, Desai RS. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study. J Oral Maxillofac Pathol. 2018;22:353-9. |
PMid:30651680 |
18. Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2014;107:378. |
PMid:25475564 |
19. Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:e5-7. |
PMid:27209484 |
20. Faden DL, Algazi A. Durable treatment of ameloblastoma with single agent BRAFi re: clinical and radiographic response with combined BRAF targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2016;109. |
PMid:27671684 |
21. Broudic-Guibert M, Blay JY, Vazquez L, Evrard A, Karanian M, Taïeb S, et al. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. J Med Case Rep. 2019;13:245. |
PMid:31340860 PMCid:PMC6657072 |
22. Fernandes GS, Girardi DM, Bernardes JPG, Fonseca FP, Fregnani ER. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. BMC Cancer. 2018;18:887. |
PMid:30208863 PMCid:PMC6134697 |
23. Cantwell‑Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385-94. |
PMid:21388974 |
24. Garnett MJ, Marais R. Guilty as charged: B‑RAF is a human oncogene. Cancer Cell. 2004;6:313-9. |
PMid:15488754 |
25. McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, et al. Ameloblastoma: A clinical review and trends in management. Eur Arch Otorhinolaryngol. 2016;273:1649-61. |
PMid:25926124 |
26. Chang J, Wang YP, Chiang CP. Clinicopathologic correlations of BRAF V600E mutation and BRAF V600E immunohistochemistry in ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:e155. |
27. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation‑specific monoclonal antibody. Acta Neuropathol. 2011;122:11‑9. |
PMid:21638088 |